IDH2 and acute myeloid leukemia: Despite the advances made in the last 40 years, the survival rates for AML are less than desirable, remaining around 70% at 5 years, even for good responders to induction therapy.(2) New therapies are already being used for gene variants of AML, such as FLT3 (midostaurin and gilterinib), BCL2 (venetoclax), and IDH1/IDH2 (ivosidenib and enasidenib) inhibitors.(3) However, such alternative therapies are not yet widely used, either because of their cost or because they require approval for use in Brazil.